The partnership looks to develop vaccines using Intravacc’s outer membrane vesicles (OMV) tech and Cristal Therapeutics’ copper-free click chemistry reagent with an initial target being COVID-19.
The two companies will work together to develop novel vaccine programs with initial work during the evaluation period taking place at Cristal’s facility, followed by the further work conducted at Intravacc’s facility, both in the Netherlands. Financial details of the collaboration have not been divulged.
Initially, the partnership is targeting a vaccine against COVID-19. Despite an influx of vaccine approvals against this virus, a spokesperson from Cristal said the current ongoing pandemic requires continued research for vaccine and treatment options, especially considering the virus mutations that we are currently seeing.
Image: iStock/Yakobchuk